Sarah Fernandes, Pharm.D, Ph.D.
Director, Program Management
Sarah Fernandes, Pharm.D., Ph.D. joined Circle Pharma in January 2022 as our Director of Program Management. Before joining the Circle Pharma team, Dr. Fernandes supported several Neuroscience and Cardiovascular programs through IND and Phase 1 at Bristol Myers Squibb, following the company’s acquisition of MyoKardia. Dr. Fernandes started working in Myokardia’s research department in 2014. Here, she oversaw the establishment of pharmacology assays, as well as the preclinical studies that supported the IND and development of the sarcomere modulators Mavacamten and Danicamtiv. In 2019, Dr. Fernandes integrated MyoKardia’s project management team. She partnered with project leaders to help molecules progress from lead optimization to IND. She also contributed to the organization of Scientific Advisory Boards and led MyoKardia’s Scientific Research Grant Program.
Dr. Fernandes holds a Pharm.D. from the University of Burgundy, a Master’s in Pharmacology from the University of Paris Sud, and a Ph.D. in Molecular and Cellular Biology from Nantes University (France). Dr Fernandes completed her postdoctoral training at the University of Washington in Seattle.